Galmed Pharmaceuticals Ltd. buy Royal Bank of Canada
Start price
11.01.24
/
50%
€0.41
Target price
11.01.25
€63.93
Performance (%)
-13.04%
Price
03.05.24
€0.36
Summary
This prediction is currently active. The price of Galmed Pharmaceuticals Ltd. has decreased since the start of the prediction. Compared to the start price this results in a performance of -13.04%. This prediction currently runs until 11.01.25. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Galmed Pharmaceuticals Ltd. | -2.174% | -2.174% |
iShares Core DAX® | -0.922% | -1.993% |
iShares Nasdaq 100 | 0.371% | -0.868% |
iShares Nikkei 225® | 2.224% | -5.187% |
iShares S&P 500 | -0.026% | -0.918% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Galmed Pharmaceuticals Ltd. diskutieren
Globus Medical, Inc. (NYSE: GMED) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $70.00 price target on the stock.
Ratings data for GMED provided by MarketBeat